August 23, 2021
Ono Pharmaceutical said on August 20 that its BRAF inhibitor Braftovi (encorafenib) has been approved in South Korea for the treatment of certain patients with colorectal cancer in combination with Erbitux (cetuximab), an EGFR inhibitor. The drug was granted approval...read more